Journal
EUROPEAN JOURNAL OF CELL BIOLOGY
Volume 91, Issue 1, Pages 31-35Publisher
ELSEVIER GMBH
DOI: 10.1016/j.ejcb.2011.01.007
Keywords
Epstein-Barr virus; CD4+T cell; Antigen; Immunodominance; Therapy
Categories
Ask authors/readers for more resources
Epstein-Barr virus (EBV) establishes lifelong persistent infections in humans and has been implicated in the pathogenesis of several human malignancies. Protective immunity against EBV is mediated by T cells, as indicated by an increased incidence of EBV-associated malignancies in immunocompromised patients, and by the successful treatment of EBV-associated post-transplant lymphoproliferative disease (PTLD) in transplant recipients by the infusion of polyclonal EBV-specific T cell lines. To implement this treatment modality as a conventional therapeutic option, and to extend this protocol to other EBV-associated diseases, generic and more direct approaches for the generation of EBV-specific T cell lines enriched in disease-relevant specificities need to be developed. To this aim, we studied the poorly defined EBV-specific CD4+ T cell response during acute and chronic infection. (C) 2011 Elsevier GmbH. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available